Suppression of activin A signals inhibits growth of malignant pleural mesothelioma cells

British Journal of Cancer

Volumn 107, Issue 12, 2012, Pages 1978-1986

  Hoda, M A ^a,b   Munzker J ^b   Ghanim, B ^a   Schelch, K ^b   Klikovits, T ^a   Laszlo, V ^a   Sahin, E ^b   Bedeir, A ^b   Lackner, A ^b   Dome, B ^a,c   Setinek, U ^d   Filipits, M ^b   Eisenbauer, M ^b   Kenessey, I ^e   Torok S ^c   Garay, T ^e   Hegedus, B ^a,b,e   Catania, A ^f   Taghavi, S ^a   Klepetko, W ^a   Berger, W ^b   Grusch, M ^b   more..

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c NATIONAL KORANYI INSTITUTE OF PULMONOLOGY   (Hungary)

^d OTTO WAGNER HOSPITAL   (Austria)

^e SEMMELWEIS UNIVERSITY   (Hungary)

^f FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

activin; activin receptor; mesothelioma; SMAD signalling; targeted therapy

Indexed keywords

4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; A 8301; ACTIVIN A; ACTIVIN RECEPTOR 1; ACTIVIN RECEPTOR 2; ANTINEOPLASTIC AGENT; CYCLIN D1; CYCLIN D3; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE INHIBITOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL MIGRATION; CELL VIABILITY; CLONOGENESIS; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PLEURA MESOTHELIOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

ACTIVINS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN D; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; IMMUNOHISTOCHEMISTRY; MESOTHELIOMA; PHENOTYPE; PHOSPHORYLATION; PLEURAL NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; TUMOR STEM CELL ASSAY; UP-REGULATION;

EID: 84870818616     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.519     Document Type: Article

References (42)

1. Antsiferova M, Huber M, Meyer M, Piwko-Czuchra A, Ramadan T, MacleodAS, Havran WL, Dummer R, Hohl D, Werner S (2011) Activin enhancesskin tumourigenesis and malignant progression by inducing a protumourigenicimmune cell response. Nat Commun 2: 576
2. Burdette JE, Jeruss JS, Kurley SJ, Lee EJ, Woodruff TK (2005) Activin Amediates growth inhibition and cell cycle arrest through Smads inhuman breast cancer cells. Cancer Res 65: 7968-7975
3. Chang KP, Kao HK, Liang Y, Cheng MH, Chang YL, Liu SC, Lin YC, Ko TY,Lee YS, Tsai CL, Wang TH, Hao SP, Tsai CN (2010) Overexpression ofactivin A in oral squamous cell carcinoma: association with poorprognosis and tumor progression. Ann Surg Oncol 17: 1945-1956
4. Chen W, Woodruff TK, Mayo KE (2000) Activin A-induced HepG2 liver cellapoptosis: involvement of activin receptors and smad proteins.Endocrinology 141: 1263-1272
5. Fitzpatrick DR, Bielefeldt-Ohmann H, Himbeck RP, Jarnicki AG, Marzo AL,Robinson BW (1994) Transforming growth factor-beta: antisense RNAmediatedinhibition affects anchorage-independent growth, tumorigenicityand tumor-infiltrating T-cells in malignant mesothelioma. GrowthFactors 11: 29-44
6. Frost K, Seir K, Lackner A, Grusch M, Grasl-Kraupp B, Schulte-Hermann R,Rodgarkia-Dara C (2011) Inhibin/activin expression in human androdent liver: subunits alpha and betaB as new players in humanhepatocellular carcinoma? Br J Cancer 104: 1303-1312
7. Gold E, Jetly N, O'Bryan MK, Meachem S, Srinivasan D, Behuria S, Sanchez-Partida LG, Woodruff T, Hedwards S, Wang H, McDougall H, Casey V,Niranjan B, Patella S, Risbridger G (2009) Activin C antagonizes activin Ain vitro and overexpression leads to pathologies in vivo. Am J Pathol 174:184-195
8. Grusch M, Drucker C, Peter-Vorosmarty B, Erlach N, Lackner A, Losert A,Macheiner D, Schneider WJ, Hermann M, Groome NP, Parzefall W,Berger W, Grasl-Kraupp B, Schulte-Hermann R (2006) Deregulationof the activin/follistatin system in hepatocarcinogenesis. J Hepatol 45:673-680
9. Grusch M, Petz M, Metzner T, Ozturk D, Schneller D, Mikulits W (2010)The crosstalk of RAS with the TGF-beta family during carcinomaprogression and its implications for targeted cancer therapy. Curr CancerDrug Targets 10: 849-857
10. Hempen PM, Zhang L, Bansal RK, Iacobuzio-Donahue CA, Murphy KM,Maitra A, Vogelstein B, Whitehead RH, Markowitz SD, Willson JK, YeoCJ, Hruban RH, Kern SE (2003) Evidence of selection for clones havinggenetic inactivation of the activin A type II receptor (ACVR2) gene ingastrointestinal cancers. Cancer Res 63: 994-999
11. Hoda MA, Mohamed A, Ghanim B, Filipits M, Hegedus B, Tamura M, BertaJ, Kubista B, Dome B, Grusch M, Setinek U, Micksche M, Klepetko W,Berger W (2011) Temsirolimus inhibits malignant pleural mesotheliomagrowth in vitro and in vivo: synergism with chemotherapy. J ThoracOncol 6: 852-863
12. Inman GJ, Nicolas FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, LapingNJ, Hill CS (2002) SB-431542 is a potent and specific inhibitor oftransforming growth factor-beta superfamily type I activin receptorlikekinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 62:65-74
13. Jackman DM (2009) Current options for systemic therapy in mesothelioma.Semin Thorac Cardiovasc Surg 21: 154-158
14. Jeruss JS, Sturgis CD, Rademaker AW, Woodruff TK (2003) Downregulationof activin, activin receptors, and Smads in high-grade breastcancer. Cancer Res 63: 3783-3790
15. Jung B, Doctolero RT, Tajima A, Nguyen AK, Keku T, Sandler RS, CarethersJM (2004) Loss of activin receptor type 2 protein expression inmicrosatellite unstable colon cancers. Gastroenterology 126: 654-659
16. Kelly RJ, Sharon E, Hassan R (2011) Chemotherapy and targeted therapiesfor unresectable malignant mesothelioma. Lung Cancer 73: 256-263
17. Musk AW, Olsen N, Alfonso H, Reid A, Mina R, Franklin P, Sleith J,Hammond N, Threlfall T, Shilkin KB, de Klerk NH (2011) Predictingsurvival in malignant mesothelioma. Eur Respir J 38: 1420-1424
18. Ogawa T, Yogo K, Ishida N, Takeya T (2003) Synergistic effects of activinand FSH on hyperphosphorylation of Rb and G1/S transition in ratprimary granulosa cells. Mol Cell Endocrinol 210: 31-38
19. Peto J, Decarli A, La Vecchia C, Levi F, Negri E (1999) The Europeanmesothelioma epidemic. Br J Cancer 79: 666-672
20. Razanajaona D, Joguet S, Ay AS, Treilleux I, Goddard-Leon S, Bartholin L,Rimokh R (2007) Silencing of FLRG, an antagonist of activin, inhibitshuman breast tumor cell growth. Cancer Res 67: 7223-7229
21. Risbridger GP, Schmitt JF, Robertson DM (2001) Activins and inhibins inendocrine and other tumors. Endocr Rev 22: 836-858
22. Robinson BW, Lake RA (2005) Advances in malignant mesothelioma.N Engl J Med 353: 1591-1603
23. Sagmeister S, Eisenbauer M, Pirker C, Mohr T, Holzmann K, Zwickl H,Bichler C, Kandioler D, Wrba F, Mikulits W, Gerner C, Shehata M,Majdic O, Streubel B, Berger W, Micksche M, Zatloukal K, Schulte-Hermann R, Grasl-Kraupp B (2008) New cellular tools reveal complexepithelial-mesenchymal interactions in hepatocarcinogenesis. Br JCancer 99: 151-159
24. Seder CW, Hartojo W, Lin L, Silvers AL, Wang Z, Thomas DG, Giordano TJ,Chen G, Chang AC, Orringer MB, Beer DG (2009a) INHBA overexpressionpromotes cell proliferation and may be epigeneticallyregulated in esophageal adenocarcinoma. J Thorac Oncol 4: 455-462
25. Seder CW, Hartojo W, Lin L, Silvers AL, Wang Z, Thomas DG, Giordano TJ,Chen G, Chang AC, Orringer MB, Beer DG (2009b) Upregulated INHBAexpression may promote cell proliferation and is associated with poorsurvival in lung adenocarcinoma. Neoplasia 11: 388-396
26. Socinski MA (2011) Multitargeted receptor tyrosine kinase inhibition: anantiangiogenic strategy in non-small cell lung cancer. Cancer Treat Rev37: 611-617
27. Stove C, Vanrobaeys F, Devreese B, Van Beeumen J, Mareel M, Bracke M(2004) Melanoma cells secrete follistatin, an antagonist of activinmediatedgrowth inhibition. Oncogene 23: 5330-5339
28. Su GH, Bansal R, Murphy KM, Montgomery E, Yeo CJ, Hruban RH, KernSE (2001) ACVR1B (ALK4, activin receptor type 1B) gene mutations inpancreatic carcinoma. Proc Natl Acad Sci USA 98: 3254-3257
29. Sugarbaker DJ, Garcia JP, Richards WG, Harpole Jr. DH, Healy-Baldini E,DeCamp Jr. MM, Mentzer SJ, Liptay MJ, Strauss GM, Swanson SJ (1996)Extrapleural pneumonectomy in the multimodality therapy of malignantpleural mesothelioma. Results in 120 consecutive patients. Ann Surg 224:288-294; (discussion 294-286)
30. Suzuki E, Kim S, Cheung HK, Corbley MJ, Zhang X, Sun L, Shan F, Singh J,Lee WC, Albelda SM, Ling LE (2007) A novel small-molecule inhibitor oftransforming growth factor beta type I receptor kinase (SM16) inhibitsmurine mesothelioma tumor growth in vivo and prevents tumorrecurrence after surgical resection. Cancer Res 67: 2351-2359
31. Tanaka T, Toujima S, Umesaki N (2004) Activin A inhibits growthinhibitorysignals by TGF-beta1 in differentiated human endometrialadenocarcinoma cells. Oncol Rep 11: 875-879
32. Tsuchida K, Nakatani M, Hitachi K, Uezumi A, Sunada Y, Ageta H,Inokuchi K (2009) Activin signaling as an emerging target for therapeuticinterventions. Cell Commun Signal 7: 15
33. Vejda S, Erlach N, Peter B, Drucker C, Rossmanith W, Pohl J, Schulte-Hermann R, Grusch M (2003) Expression of activins C and Einduces apoptosis in human and rat hepatoma cells. Carcinogenesis 24:1801-1809
34. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P,Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P(2003) Phase III study of pemetrexed in combination with cisplatinversus cisplatin alone in patients with malignant pleural mesothelioma.J Clin Oncol 21: 2636-2644
35. Wang Q, Wen YG, Li DP, Xia J, Zhou CZ, Yan DW, Tang HM, Peng ZH(2010) Upregulated INHBA expression is associated with poor survival ingastric cancer. Med Oncol 29(1): 77-83
36. Wang QF, Tilly KI, Tilly JL, Preffer F, Schneyer AL, Crowley Jr. WF, SlussPM (1996) Activin inhibits basal and androgen-stimulated proliferationand induces apoptosis in the human prostatic cancer cell line, LNCaP.Endocrinology 137: 5476-5483
37. Werner S, Alzheimer C (2006) Roles of activin in tissue repair, fibrosis, andinflammatory disease. Cytokine Growth Factor Rev 17: 157-171
38. Yamato K, Koseki T, Ohguchi M, Kizaki M, Ikeda Y, Nishihara T (1997)Activin A induction of cell-cycle arrest involves modulation of cyclin D2and p21CIP1/WAF1 in plasmacytic cells. Mol Endocrinol 11: 1044-1052
39. Ying S, Zhang Z, Batres Y, Zhao Y, Lin S, Li G (1997) p53 is involved in theinhibition of cell proliferation mediated by activin A in cultured humanprostate cancer LNCaP cells. Int J Oncol 11: 591-595
40. Yoshinaga K, Mimori K, Yamashita K, Utsunomiya T, Inoue H, Mori M(2003) Clinical significance of the expression of activin A in esophagealcarcinoma. Int J Oncol 22: 75-80
41. Yoshinaga K, Yamashita K, Mimori K, Tanaka F, Inoue H, Mori M (2008)Activin a causes cancer cell aggressiveness in esophageal squamous cellcarcinoma cells. Ann Surg Oncol 15: 96-103
42. Zucali PA, Giaccone G (2006) Biology and management of malignantpleural mesothelioma. Eur J Cancer 42: 2706-2714